Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EFFECT OF ANTIHYPERTENSIVE THERAPY ON METABOLIC PROFILE AND ERECTILE FUNCTION IN HYPERTENSIVE MEN WITH HIGH CARDIOVASCULAR RISK: FOCUS ON THE COMBINATION OF LISINOPRIL AND AMLODIPINE

https://doi.org/10.20996/1819-6446-2010-6-4-491-496

Full Text:

Abstract

Aim. To study the antihypertensive and metabolic effects of lisinopril plus amlodipine combination in hypertensive men with high cardiovascular risk.

Materials and methods. Hypertensive men (n=21) with high cardiovascular risk (SCORE scale >5%) aged 30-59 y.o. were included in the study. Questionnaire survey, blood pressure (BP) and heart rate measuring, anthropometric studies, evaluation of the plasma lipid profile, uric acid level and glucose tolerance test were performed at baseline and at the end of the study. Erectile function was assessed by International index of erectile function (IIEF) score. After the cancellation of previous antihypertensive drugs patients were prescribed lisinopril 10 mg QD and amlodipine 5 mg QD. The duration of the study was 6 months.

Results. In 4 weeks of the treatment systolic and diastolic BP decreased by 9.3 and 5.2%, and in 24 weeks – by 14.7 and 7.2% respectively (p<0.05). Target BP levels were achieved in 85% of patients. Antihypertensive therapy during 6 months had no significant effect on the plasma lipid profile, glucose and uric acid levels. The mild to moderate-mild erectile dysfunction were detected in 35% of men before therapy. Erectile function indices in hypertensive men with high cardiovascular risk had not changed during combined antihypertensive therapy.

Conclusion. Antihypertensive therapy with lisinopril and amlodipine in hypertensive men with high cardiovascular risk during 6 months led to a statistically significant reduction of BP level without affect plasma lipid profile, glucose and uric acid levels as well as erectile function.

About the Authors

M. N. Mamedov
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


M. V. Stroeva
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


M. N. Kovrigina
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


E. A. Poddubskaya
State Research Center for Preventive Medicine
Russian Federation
Petroverigsky per. 10, Moscow, 101990


References

1. Mancia G., Laurent S.,Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47.

2. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008;7(6):1-32.

3. Оганов Р.Г., Мамедов М.Н., редакторы. Школа по диагностике и лечению метаболического синдрома. Пособие для врачей. М.: Медицинская книга; 2007.

4. НебиеридзеД.В., Оганов Р.Г.Метаболические и сосудистые эффекты антигипертензивной терапии. М.: Универсум Паблищинг; 2005.

5. Rosen R.C. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl 1997;1:47-51.

6. Ferrario C.M., Levy P. Sexual dysfunction in patients with hypertension: implications fortherapy. J Clin Hypertens (Greenwich) 2002;4(6):424- 32.

7. Лоран О.Б., Сегал А.С., Верткин А.Л. и др. Клиническая эффективность и влияние бета-адреноблокаторов на копулятивную функцию у больных с артериальной гипертензией. Кардиология 2002;(9):39-42.

8. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.

9. Rosen R.C., Riley A., Wagner G. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49(6):822-30.

10. Оганов Р.Г. Концепция факторов риска как основа профилактики сердечно-сосудистых заболеваний. Врач 2001; 7:3-6.

11. Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case — control study). Lancet 2004; 364(9438): 937-52.

12. Bartnik M., Ryden L., Ferrari R. et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Euro￾pe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25(21):1880-90.

13. Alderman M.H. Serum Uric Acid As a Cardiovascular Risk FactorforHeart Disease. Curr Hypertens Rep 2001;3(3):184-9.

14. Yusuf S., Sleight P., Pogue J. et al. HOPE study investigators. Effects of an angiotensin-converting-enzime inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145-53.

15. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353(9153):611-6

16. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М.: МИА; 2006.

17. Sanjuliani A.F., Francischetti E.A., Genelhu de Abreu V., Ueleres Braga J. Effects of moxonidine on the sympathetic nervous system, blood pressure, plasma rennin activity, plasma aldosterone, leptin, and metabolic profile in obese hypertensive patients. J Clin Basic Cardiol 2004;7(1- 4):19-25.

18. Dahl f B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpointreduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359(9311):995-1003.

19. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426):1198-204.

20. Dahl f B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in theAnglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489):895-906.

21. Pepine C., Handberg E.M., Cooper-deHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.JAMA 2003; 290(21):2805-16.

22. Weber M.A., Bakris G.L., Dahl f B. et al Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007;16(1):13-9.

23. Destro M., Luckow A., Samson M. et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study:the EX-EFFeCTS Study.JAm SocHypertens 2008;2(4):294-302.

24. Barrios V., Escobar C., Echarri R. Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. VascHe￾alth Risk Manag 2008;4(4):847-53.

25. Della Chiesa A., Pfiffner D., Meier B., Hess O.M. Sexual activity in hypertensive men. J Hum Hypertens 2003;17(8):515-21.

26. Моисеев С.В., Фомин В.В. Блокаторы рецепторов ангиотензина II и сексуальная функция у мужчин и женщин. Клиническая фармакология и терапия 2006;15(3):43-48.

27. Мамедов М.Н. Стратегия единого подхода к диагностике и лечению эректильной дисфункции, андроген-дефицитного состояния и сердечно-сосудистых заболеваний. М.: Медицинская книга; 2009.


For citation:


Mamedov M.N., Stroeva M.V., Kovrigina M.N., Poddubskaya E.A. EFFECT OF ANTIHYPERTENSIVE THERAPY ON METABOLIC PROFILE AND ERECTILE FUNCTION IN HYPERTENSIVE MEN WITH HIGH CARDIOVASCULAR RISK: FOCUS ON THE COMBINATION OF LISINOPRIL AND AMLODIPINE. Rational Pharmacotherapy in Cardiology. 2010;6(4):491-496. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-4-491-496

Views: 354


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)